Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
55 participants
OBSERVATIONAL
2005-03-31
2005-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In healthy individuals, the metabolic response to hemorrhage, burns and injury is characterized by a hyperdynamic metabolic response that upregulates the proinflammatory/immunologic/metabolic "milieu" and is designed to heal injury, combat infection and prevent death. This inflammatory response on the part of the patient is both functional and adaptive from a physiologic perspective (9). Aging is known to decrease physiologic reserve and may play a role in altering the ability of the injured elderly patient to mount an adaptive, appropriate, inflammatory response when injured (10). Some evidence exists that documents the age-related decline of immunologic function in the elderly, particularly that portion of the immune response described as cell mediated immunity \[CMI\] (11). This contributes to the higher increase in infections in the elderly (12). There is also animal model evidence that immune function is worsened when combined with injury (13). Similarly, hemorrhage, burns and injury also depress cell mediated immunity in previously healthy individuals increasing the likelihood of infection and organ system failure as a result (14). Little is known, however, about the nature of the immuno/inflammatory response to injury in the elderly. Therefore, one of the hypotheses of our study is that the aging process attenuates this immuno/inflammatory response process, adversely impacting the function of the nonspecific portion of the immune defense system and the main component of that system, the polymorphonuclear leukocyte (PMN).
The systemic immuno/inflammatory response to hemorrhage, burns and injury is well characterized in young, healthy volunteers and animal models and has been studied extensively (15). The key feature of this response is the attraction of PMNs to the site of injury. These are "mature" PMNs that are present in the peripheral bloodstream that possess a life span of approximately 3-5 days. When activated, these cells are responsible for limiting microbial invasion and promoting wound healing. However, prolonged activation of these cells is deleterious as it can lead to perpetuation of the inflammatory response, exacerbating tissue injury and leading to the development of organ system injury, and the condition known as multi-system organ failure. Under normal circumstances, the process of apoptosis, or programmed cellular death, limits the life span of the PMN to 2-3 days and serves to regulate the extent of the immuno/inflammatory response. This allows sufficient time for the acquired immune system to be activated and come on line in response to the cell mediated activity against infection and antigen. Many of the normal functions of the innate, non-specific PMN dependent, immune system are known to be dysfunctional in younger patients who have sepsis, severe injury or shock. It is unclear, however, if the same impact is present in elderly patients who have been injured because little is known about the function of the PMNs in elderly patients in general, and, specifically in those elderly patients who have been injured. Since elderly patients have known, age related depressed cell mediated immunity, our second hypothesis is that there may be age related abnormalities present in the PMNs of elderly patients who have been injured that contribute to the worse outcomes following injury.
The purpose of this study is to begin to characterize the functional status of a portion of the innate immune response following injury in elderly trauma patients. This will be accomplished through analysis of a standard battery of functional tests that characterize PMNs regarding apoptosis and responses to immune challenges. These PMN functionality tests will be correlated with observed clinical outcomes. The null hypothesis for this study is that PMNs from elderly trauma patients have functional characteristics that result in different local and systemic effects than PMN's from non-injured elder controls or non-injured non-elder controls and that this may lead to different effects post injury that impact outcomes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Admitted to the trauma service
Exclusion Criteria
* Immunocompromised
* Currently receiving systemic corticosteroids
* Participation in other studies
* In the opinion of the investigator will not be able to complete protocol
66 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Summa Health System
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Summa Health System
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
William Fallon, MD
Role: PRINCIPAL_INVESTIGATOR
Summa Health System
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Summa Health System
Akron, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
04104
Identifier Type: -
Identifier Source: org_study_id